References
- 1. M. C. Andre, J. F. Hausman and G. Guerriero, Cannabis sativa: The plant of the thousand and one molecules, Front. Plant. Sci. 19 (2016) 1–17; https://doi.org/10.3389/fpls.2016.0001910.3389/fpls.2016.00019
- 2. D. Namdar, M. Mazuz, A. Ion and H. Koltai, Variation in the compositions of cannabinoid and terpenoids in Cannabis sativa derived from inflorescence position along the steam and extraction, Ind. Crops. Prod. 113 (2018) 376–382; https://doi.org/10.1021/acs.jnatprod.5b0094910.1021/acs.jnatprod.5b00949
- 3. J. C. Turner, J. K. Hemphill and P. G. Mahlberg, Quantitative determination of cannabinoids in individual glandular trichomes of Cannabis sativa L. (Cannabaceae), Am. J. Bot.65 (1978) 1103–1106; https://doi.org/10.1002/j.1537-2197.1978.tb06177.x10.1002/j.1537-2197.1978.tb06177.x
- 4. K. W. Hillig and P. G. Mahlberg, A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae), Am. J. Bot. 91 (2004) 966–975; https://doi.org/10.3732/ajb.91.6.96610.3732/ajb.91.6.966
- 5. G. T. DeLong, C. E. Wolf, A. Poklis and A. H. Lichtman, Pharmacological evaluation of the neutral constituent of Cannabis sativa, cannabichromene and its modulation by delta-9-tetrahidorcannabinol, Drug Alcohol. Depend. 112 (2010) 126–133; https://doi.org/10.1016/j.drugalcdep.2010.05.01910.1016/j.drugalcdep.2010.05.019
- 6. E. B. Russo and J. Marcu, Cannabis pharmacology: The usual suspects and a few promising leads, Adv. Pharmacol. 80 (2017) 67–134; https://doi.org/10.1016/bs.apha.2017.03.00410.1016/bs.apha.2017.03.004
- 7. D. Pacifico, F. Miselli and A. Carboni, Time course of cannabinoid accumulation and chemotype development during the growth of Cannabis sativa L., Euphytica160 (2008) 231–240; https://doi.org/10.1007/s10681-007-9543-y10.1007/s10681-007-9543-y
- 8. E. Small and H. D. Beckstead, Common cannabinoid phenotypes in 350 stocks of Cannabis, Lloydia36 (1973) 144–165.
- 9. G. Fournier, C. Richez-Dumanois, J. Duvezin and J. P. Mathieu, Identification of a new chemotype in Cannabis sativa: cannabigerol-dominant plants, biogenetic and agronomic prospects, Planta Med. 53 (1987) 277–280; https://doi:10.1055/s-2006-96270510.1055/s-2006-962705
- 10. J. R. Valle, J. E. V. Vieira, J. G. Auce′lio and I. F. M. Valio, Influence of photoperiodism on cannabinoid content of Cannabis sativa L., Bull. Narc.30 (1978) 67–68.
- 11. D. W. Pate, Chemical ecology of Cannabis, J. Int. Hemp Assoc.29 (1994) 32–37.
- 12. F. A. Bazzaz, D. Dusek, D. S. Seigler and A. W. Haney, Photosynthesis and cannabinoid content of temperate and tropical populations of Cannabis sativa, Biochem. Syst. Ecol.3 (1975) 15–18; https://doi.org/10.1016/0305-1978(75)90036-810.1016/0305-1978(75)90036-8
- 13. I. Bocsa, P. Mathe and L. Hangyel, Effect of nitrogen on tetrahydrocannabinol (THC) content in hemp (Cannabis sativa L.) leaves at different positions, J. Int. Hemp Assoc.4 (1997) 80–81.
- 14. C. B. Coffman and W. A. Gentner, Responses of greenhouse grown Cannabis sativa L. to nitrogen, phosphorous, and potassium, Agron. J.69 (1977) 832–836; https://doi.org/10.2134/agronj1977.00021962006900050026x10.2134/agronj1977.00021962006900050026x
- 15. E. H. Small, D. Beckstead and A. Chan, The evolution of cannabinoid phenotypes in Cannabis, Econ. Bot.29 (1975) 219–232.10.1007/BF02873168
- 16. Y. Gaoni and R. Mechoulam, Cannabichromene a new active principle in hashish, Chem. Commun.1 (1966) 20–21.
- 17. S. Sirikantaramas, F. Taura, S. Morimoto and Y. Shoyama, Recent advances in Cannabis sativa research: biosynthetic studies and its potential in biotechnology, Curr. Pharm. Biotechnol.8 (2007) 237–243; https://doi.org/10.2174/13892010778138745610.2174/138920107781387456
- 18. M. Fellermeier and M. H. Zenk, Prenylation of olivetolate by a hemp transferase yields cannabigerolic acid the precursor of tetrahydrocannabinol, FEBS Lett.427 (1998) 283–285; https://doi.org/10.1016/S0014-5793(98)00450-510.1016/S0014-5793(98)00450-5
- 19. D. F. Wong, H. Kuwabara, A. G. Horti, V. Raymont, J. Brasic, M. Guavera, W. Ye, R. F. Dannals, H. T. Ravert, A. Nandi, A. Rahmim, J. E. Ming, I. Grachev, C. Roy and N. Cascella, Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PTE radioligand (11C)OMAR, Neuroimage52 (2010) 1505–1513; http://doi.org:10.1016/j.neuroimage.2010.04.03410.1016/j.neuroimage.2010.04.034658086220406692
- 20. T. Lowin and R. H. Straub, Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis, Arthritis Res. Ther.17 (2015) 226; https://doi.org/10.1186/s13075-015-0743-x10.1186/s13075-015-0743-x456116826343051
- 21. C. Muller, P. Morales and P. H. Reggio, Cannabinoid ligands targeting TRP channels, Front. Mol. Neurosci. 11 (2019) Article ID 487 (16 pages); https://doi.org/10.3389/fnmol.2018.0048710.3389/fnmol.2018.00487634099330697147
- 22. Y. Gaoni and R. Mechoulam, The structure and function of cannabigerol, a new hashish constituent, Proc. Chem. Soc. 1 (1964) 82–83.10.1039/sa9640100082
- 23. M. G. Cascio, L. A. Gauson, L. A. Stevenson, R. A. Ross and R. G. Pertwee, Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist, Br. J. Pharmacol.159 (2010) 129–141; https://doi.org/10.1111/j.1476-5381.2009.00515.x10.1111/j.1476-5381.2009.00515.x282335920002104
- 24. H. N. Eisohly, C. E. Turner, A. M. Clark and M. A. Elsohly, Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds, J. Pharm. Sci. 71 (1982) 1319–1323; https://doi.org/10.1002/jps.260071120410.1002/jps.26007112047153877
- 25. F. Pollastro, O. Taglialatela-Scafati, M. Allara, E. Munoz, V. Di Marzo, L. De Petrocellis and G. Appendino, Bioactive prenylogus cannabinoid from fiber hemp, J. Nat. Prod. 74 (2011) 2019–2020; https://doi.org/10.1021/np200500p10.1021/np200500p21902175
- 26. N. Iwata and S. Kitanaka, New cannabinoid-like chromane and chromene derivatives from Rhododendron anthopogonoides, Chem. Pharm. Bull.59 (2011) 1409–1412; https://doi.org/10.1248/cpb.59.140910.1248/cpb.59.140922041081
- 27. L. De Petrocellis, A. Ligresti, A. S. Moriello, M. Allara, T. Bisogno, S. Petrosino, C. G. Stott and V. Di Marzo, Effects of cannabinoids and cannabinoid-enriched cannabis extracts on TRP channels and endocannabinoid metabolic enzymes, Br. J. Pharmacol. 163 (2011) 1479–1494; https://doi.org/10.1111/j.1476-5381.2010.01166.x10.1111/j.1476-5381.2010.01166.x316595721175579
- 28. A. A. Izzo, R. Capasso, G. Aviello, F. Borrelli, B. Romano, F. Piscitelli, L. Gallo, F. Capasso, P. Orlando and V. Di Marzo, Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice, Br. J. Parmacol. 166 (2012) 1444–1460; https://doi.org/10.1111/j.1476-5381.2012.01879.x10.1111/j.1476-5381.2012.01879.x341745922300105
- 29. F. Taura, S. Morimoto, Y. Shoyama and R. Mechoulam, First direct evidence for the mechanism of delta-1-tetrahydrocannabinolic acid biosynthesis, J. Am. Chem. Soc. 38 (1995) 9766–9767; https://doi.org/10.1021/ja00143a02410.1021/ja00143a024
- 30. F. Taura, S. Morimoto and Y. Shoyama, Purification and characterization of cannabidiolic-acid synthase from Cannabis sativa L., J. Biol. Chem.271 (1996) 17411–17416; https://doi.org/10.1074/jbc.271.29.1741110.1074/jbc.271.29.174118663284
- 31. E. P. M. De Meijer, M. Bagatta, A. Carboni, P. Crucitti, V. M. Cristiana Moliterni, P. Ranalli and G. Mandolino, The inheritance of chemical phenotype in Cannabis sativa L., Genetics163 (2003) 335–346.10.1093/genetics/163.1.335146242112586720
- 32. E. P. M. De Meijer and K. M. Hammond, The inheritance of chemical phenotype in Cannabis sativa L. (II): Cannabigerol predominant plants, Euphytica145 (2005) 189–198; https://doi.org/10.1007/s10681-005-1164-810.1007/s10681-005-1164-8
- 33. E. P. M. De Meijer and K. M. Hammond, The inheritance of the chemical phenotype in Cannabis sativa L. (III): variation in cannabichromene proportion, Euphytica165 (2009) 293–331; https://doi.org/10.1007/s10681-008-9787-110.1007/s10681-008-9787-1
- 34. V. Di Marzo, New approaches and challenges to targeting the endocannabinoid system, Nat. Rev. Drug Discov.17 (2018) 623–639; http://doi:10.1038/nrd.2018.11510.1038/nrd.2018.11530116049
- 35. G. Appendino, S. Gibbons, A. Giana, A. Pagani, G. Grasi, M. Stavri, E. Smith and M. M. Rahman, Antibacterial cannabinoids from Cannabis sativa: A structure-activity study, J. Nat. Prod. 71 (2008) 1427–1430; https://doi.org/10.1021/np800267310.1021/np800267318681481
- 36. S. Beak, Y. O. Kim, J. S. Kwag, K. E. Choi, W. Y. Jung and D. S. Han, Boron trifluoride etherate on silica – A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells, Arch. Pharm. Res. 21 (1998) 353–356.10.1007/BF02975301
- 37. A. Ligresti, A. S. Moriello, K. Starowicz, I. Matias, S. Pisanti, L. De Petrocellis, C. Laezza, G. Portella, M. Bifulco and V. Di Marzo, Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma, J. Pharmacol. Exp. Ther. 318 (2006) 1375–1387; https://doi.org/10.1124/jpet.106.10524710.1124/jpet.106.105247
- 38. D. I. Brierley, J. Samuels, M. Duncan, B. J. Whalley and C. M. Williams, Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats, Psychopharmacology (Berlin) 233 (2016) 3603–3613; https://doi.org/10.1007/s00213-016-4397-410.1007/s00213-016-4397-4
- 39. J. A. Farrimond, B. J. Whalley and C. M. Williams, Cannabinol and cannabidiol exert opposing effects on rat feeding patterns, Psychopharmacology (Berlin) 223 (2012) 117–129; https://doi.org/10.1007/s00213-012-2697-x10.1007/s00213-012-2697-x
- 40. A. Smeriglio, S. V. Giofre, E. M. Galati, M. T. Menforte, N. Cicero, V. D‘Angelo, G. Grassi and C. Circosta, Inhibition of aldose activity by Cannabis sativa chemotypes extracts with high content of cannabidiol or cannabigerol, Fitoterapia127 (2018) 101–108; https://doi.org/10.1016/j.fitote.2018.02.00210.1016/j.fitote.2018.02.002
- 41. W. M. Davis and N. S. Hatoum, Neurobehavioral actions of cannabichromene and interactions with delta-9-tetrahydrocannabinol, Gen. Pharmacol.-Vasc. S.14 (1983) 247–252; https://doi.org/10.1016/0306-3623(83)90004-610.1016/0306-3623(83)90004-6
- 42. N. Shinjyo and V. Di Marzo, The effect of cannabichromene on adult neural stem/progenitor cells, Neurochem. Int.63 (2013) 432–437; https://doi.org/10.1016/j.neuint.2013.08.00210.1016/j.neuint.2013.08.00223941747
- 43. A. A. Izzo, F. Borrelli, R. Capasso, V. Di Marzo and R. Mechoulam, Non-psychotropic plant cannabinoids: new therapeutic opportunities from ancient herb, Trends Pharmacol. Sci. 30 (2009) 515–527; https://doi.org/10.1016/j.tips.2009.07.00610.1016/j.tips.2009.07.00619729208
- 44. C. E. Turner and M. A. Elsohly, Biological activity of cannabichromene, its homologs and isomers, J. Clin. Pharmacol.21 (1981) 283–291; https://doi.org/10.1002/j.1552-4604.1981.tb02606.x10.1002/j.1552-4604.1981.tb02606.x7298870